

Norseld announces further approvals for the Dual Yellow Laser

The Dual Yellow laser producing outputs in both the yellow and wavelengths has now one of the widest range of approvals of any device on the market. The original FDA approval K023899 for vascular and pigmented lesions has now been supplemented by marketing approval K032397 covering all of the indications listed below. The device is also approved under CE regulations for a similar wide range of indications.

The ideal output of the Dual Yellow makes it unique amongst lasers. It produces two different wavelengths each of which uniquely target the three most important chromophores in cutaneous lesions. Whilst the Yellow output from the device is ideally absorbed by Haemoglobin and porphyrins, the Green output is optimally absorbed by melanin and also by porphyrin.

Indications treated with 578nm Yellow light .

facial telangiectasias
leg telangiectasias,
rosacea,
port wine stains,
cherry angiomas,
venus lakes,
hemangiomas,
angiomas,
leg veins,
spider angioma,
spider nevus, and
Poikiloderma of Civatte,
periorbital wrinkles
wrinkles
Acne vulgaris

Indications treated with 511nm green light.

lentigines,
solar keratoses,
adenoma sebaceum, and
trichoepitheliomas
naevi,
keratoses,
syringomas
Seborrhoeic keratoses
other epidermal lesions
scars,
striae,
psoriasis,
verrucae vulgaris, and
warts

The optimum wavelengths and pulse duration of the laser provide ideal and mostly single treatments for most vascular and pigmented lesions. The ease of use, safety and efficacy of the Dual Yellow laser places it as the system of choice especially for practices wishing to achieve best practice results with minimal outlay and best results for their clients.